PTC INC.
PTC INC. (PTC) Stock News
The latest PTC headlines and market coverage — 2 recent stories, updated throughout the day.
- The Motley Fool·
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million
PTC Therapeutics' chief technical operations officer sold 2,464 shares under a routine pre-established trading plan, generating $222,376. The insider retains substantial holdings of 63,198 shares plus 45,036 derivative securities. The sale is routine equity compensation management and not indicative of concern, as the company demonstrates strong commercial momentum with Q1 product revenue of $225.6 million, driven by PKU drug Sephience's $124.6 million in sales (up 36% quarterly). Management raised full-year product revenue guidance to $750-850 million.
- GlobeNewswire Inc.·
Eos SENOLYTIX Presents Best-in-Class Preclinical Body Composition Data Highlighting Unique Muscle Mass Gains with MitoXcel™ Geropeptide PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum
Eos SENOLYTIX presented preclinical data for its lead candidate PTC-2105, a mitochondrial-targeted geropeptide showing improvements in body composition with lean mass gains and fat reduction without the muscle loss associated with GLP-1 therapies. The company also announced a merger agreement with Pulmatrix, Inc., expected to close in Q3 2026 under the new ticker symbol MTXL. Preclinical studies demonstrated extended survival in aged mice and prevention of age-related decline.